InfuSystem Reports Q2 2026 Financial Results with Increased Revenues and Profitability

InfuSystem Holdings, Inc. reported its financial results for the second quarter and first half of 2026, revealing a slight increase in net revenues and a notable rise in profitability compared to the same periods in 2025. For the three months ended June 30, 2026, the company achieved net revenues of $36.9 million, a 2.6% increase from $36.0 million in the prior year. The net income for the quarter was $3.2 million, up from $2.6 million, resulting in a basic earnings per share of $0.16, compared to $0.12 in the previous year. For the first half of 2026, net revenues totaled $70.6 million, a marginal decrease from $70.7 million in the first half of 2025, while net income rose significantly to $4.2 million from $2.3 million.

The company's financial performance was driven primarily by its Patient Services segment, which reported a 15.2% increase in net revenues to $24.8 million, attributed to higher treatment volumes and improved collections in oncology and wound care. The Wound Care segment, in particular, saw a substantial revenue increase of 154%, bolstered by new supplier relationships and product launches. Conversely, the Device Solutions segment experienced a decline in net revenues, dropping 16.1% to $12.1 million, largely due to decreased biomedical services revenue and lower medical equipment sales.

Operationally, InfuSystem has made strategic moves to enhance its service offerings and market presence. The company completed the acquisition of Apollo Medical Supply in May 2025, which has strengthened its wound care business. Additionally, the company has focused on expanding its product portfolio, including the introduction of Pneumatic Compression Devices and Adjustable Compression Wraps, which contributed to the revenue growth in the Wound Care segment. As of June 30, 2026, InfuSystem's total assets stood at $97.7 million, with a total stockholders' equity of $59.1 million, reflecting a solid financial foundation.

In terms of operational metrics, InfuSystem reported a decrease in cash and cash equivalents to $964,000 from $3.2 million at the end of 2025, while accounts receivable increased to $27.2 million, indicating a growing customer base and potential revenue collection challenges. The company also announced a new share repurchase program, authorizing up to $20 million in stock buybacks, which is set to commence on July 1, 2026. Looking ahead, InfuSystem remains optimistic about its growth prospects, particularly in the oncology and wound care markets, while navigating the challenges posed by market conditions and operational costs.